<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_NTU-LIHPAO-Taiwan_Modeling skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:NTU-LIHPAO-Taiwan/Modeling</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>NTU-LIHPAO-Taiwan</TITLE></P><DIV id="Wrapper"><DIV id="Wrapper_TopPic"><DIV class="Slidemenu"><UL><LI><DIV class="width_small"><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan">Home</A></DIV></LI><LI><DIV class="width_small" span="" style="cursor:default"><A>Team</A></DIV></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Team">Team</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Attributions">Attributions</A></LI></UL><LI><DIV class="width_small" span="" style="cursor:default"><DIV id="Position_Now"><A>Project</A></DIV></DIV></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Description">Description</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Design">Design</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Results">Results</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Modeling">Modeling</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Experiments">Protocols</A></LI><LI><DIV class="width_small" span="" style="cursor:default"><A>Parts</A></DIV></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Parts">Team Parts</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Basic_Part">Basic Parts</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Composite_Part">Composite Parts</A></LI><LI><DIV class="width_small"><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Notebook">Notebook</A></DIV></LI><LI><DIV class="width_small"><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Safety">Safety</A></DIV></LI><LI><DIV class="width_small" span="" style="cursor:default"><A>Society</A></DIV></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Practices">Human Practices</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Collaborations">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Entrepreneurship">Entrepreneurship</A></LI></DIV></DIV><DIV id="Content_Container"><DIV id="Content"><UL class="main-Content"><LI><SPAN class="title">Modeling</SPAN></LI><LI><A href="#First1">Introduction</A></LI><LI><A href="#First2">Pathways</A></LI></UL></DIV></DIV><DIV id="Articles"><DIV class="ContentBox"><DIV class="ContentHolder"><DIV class="Text1">Modeling</DIV><DIV class="Text2" id="First1">Introduction</DIV><DIV class="Text3">
Noticing the problem of obesity growing in Taiwan, our team NTU-LIHPAO-Taiwan make efforts to improve a designed probiotic for oral peptide drug — “Healthin”. For preventing the side effects from commercial weight loss pills, as in our project design, the product CPP-PYY complex is produced by genetically modified <I>Lactobacillus casei</I>, which is orally ingested. TAT helps to penetrate through the villi, and the released PYY then binds to hypothalamus for appetite suppression.
						</DIV><DIV class="Text3">
In the Modeling part, we tried to <B>simulate the pathways of our designed probiotic <I>L. casei</I> and secreted CPP-PYY complex inside human body</B>, from oral ingestion to final PYY releasing, respectively. The ultimate goal is to <B>build the general formula, and to find out the suitable and optimal dose for Healthin</B>, which hopefully exerts the beneficial and harmless effect for appetite suppression.
						</DIV><DIV class="Text3">
In general, after taking Healthin, some <I>L. casei</I> pass through stomach and reach human intestine. Within the transient colonization, these modified <I>L. casei</I> produce CPP-PYY complex, and with the help of TAT, the complexes penetrate through the small intestine epithelial cells into circulation system. The linker between the complex is cut by thrombin in the blood, thus releasing free PYY for circulation, which binds to Y2 receptor in the hypothalamus for controlling satiety feeling. Moreover, the suicide device and bacteria survival were also considered in the simulation for safety concern. Combining data obtained from experimental results and several literatures, we applied MATLAB for calculation and simulation. By analyzing the pathways of <I>L. casei</I> inside human body step by step, the ultimate dose could be determined from the general formula.
						</DIV><DIV class="Text2" id="First2">Pathways</DIV><DIV class="Text3">
The pathways of the novel oral peptide drug Healthin consist of 5 parts, from intake through peptide release inside human body :
						</DIV><DIV class="Text3"><OL class="part2"><LI>Bacteria distribution</LI><LI>CPP-PYY penetration efficiency</LI><LI>Absorption into bloodstream</LI><LI>Thrombin cleavage efficiency</LI><LI>Healthin drug effect</LI></OL></DIV><DIV class="Text3">
By utilizing MATLAB, we built a model from these pathways to construct the general formula for determining the dose response.
						</DIV><DIV class="Text3"><B>—&gt;</B>     <A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Modeling/Pathways"><B>[Click on here to see our Simulation Strategy and Results]</B></A></DIV><DIV class="Text3"><B>—&gt;</B>     <A href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Modeling/Conclusion"><B>[Click on here for Conclusion and Application]</B></A></DIV><DIV class="Container_Article_Picture"><DIV class="Article_Picture"><DIV class="Article_PictureText"><DIV class="Text_Picture">[Fig.2-1] Pathway of Healthin</DIV></DIV></DIV></DIV><DIV class="Text_Sponsor">
							Maintained by the iGEM team NTU-LIHPAO-Taiwan    ©2015 NTU-LIHPAO-Taiwan
						</DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>